EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The immunogenicity, safety, and efficacy of N8-GP in previously untreated patients with severe hemophilia A: pathfinder6 end-of-trial results

Gili Kenet, Guy Young, Ampaiwan Chuansumrit, Tadashi Matsushita, Vandana Yadav, Marek Zak, Christoph Male

Journal of Thrombosis and Haemostasis · 2023-11 · 21 (11) · 3109-3116

DOI: 10.1016/j.jtha.2023.07.030 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Thrombosis and Haemostasis, 2023-11. Verfasst von Gili Kenet und 6 weiteren Autor:innen. Beteiligte Einrichtung: Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; The Israeli National Hemophilia Center and Thrombosis Unit, Sheba Medical Center,…. Hauptthemen laut MEDLINE: Hemophilia A, Hemostatics. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novo Nordisk.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The pathfinder6 (NCT02137850) international phase 3 trial examined immunogenicity, safety, and efficacy of the extended half-life factor VIII (FVIII) replacement product N8-GP (turoctocog alfa pegol; Esperoct) in previously untreated patients (PUPs) with hemophilia A. OBJECTIVES: We present end-of trial results for extended PUP N8-GP treatment for up to a median (range) 2.5 (0.0; 7.4) years. PATIENTS/METHODS: Longer-term N8-GP treatment in PUPs with hemophilia A was examined. The prophylaxis regimen was ∼60 IU/kg N8-GP i.v. twice weekly, or every 3 or 7 days. The primary endpoint was the incidence of FVIII inhibitors. RESULTS: Overall, 81 patients received N8-GP and were included in this analysis. The inhibitor incidence was 30.0% (15.7% high-titer [>5 BU]) for the extension phase. Patients had a median (range) 2.9 (0.1; 7.2) years of prophylaxis following the pre-prophylaxis period. During prophylaxis, the median annualized bleeding rate (ABR) (interquartile range) was 1.4 (0.6; 3.5), 13% of patients experienced no bleeding episodes, and 55.1% of patients experienced no spontaneous bleeds. The proportion of patients without any spontaneous bleeding episodes increased after the first year of prophylaxis. The hemostatic success rate in the treatment of bleeding episodes was 87.6%. No additional safety concerns were observed in patients with previously reported observation of temporarily decreased incremental recovery (IR). CONCLUSION: Long-term end-of-trial PUP N8-GP prophylaxis data indicate that PUPs respond well to long-term N8-GP treatment. The inhibitor incidence was consistent with previous results. Median ABR during prophylaxis was 1.4. There were no lasting clinical impacts or safety concerns for patients with an observation of temporarily decreased IR.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemophilia AHemostaticsHumansFactor VIIIHemorrhageHemostasis

Stichwörter der Autor:innen

antibodiesfactor VIIIhemophilia Along-term careneutralizingpediatrics

Substanzen

Factor VIIIHemostatics

Autor:innen und Institutionen

  • Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; The Israeli National Hemophilia Center and Thrombosis Unit, Sheba Medical Center, Tel Hashomer, Israel; The Amalia Biron Research Institute of Thrombos…
  • Children's Hospital Los Angeles/University of Southern California Keck School of Medicine, Los Angeles, California, USA.
  • Department of Pediatrics, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
  • Nagoya University Hospital, Nagoya, Japan.
  • Novo Nordisk Service Centre India Private Ltd, Bangalore, India.
  • Novo Nordisk A/S, Søborg, Denmark.

Förderung

  • Novo Nordisk

Zitieren

APA

Kenet, G., Young, G., Chuansumrit, A., Matsushita, T., Yadav, V., Zak, M., & Male, C. (2023). The immunogenicity, safety, and efficacy of N8-GP in previously untreated patients with severe hemophilia A: pathfinder6 end-of-trial results. Journal of Thrombosis and Haemostasis, 21(11), 3109-3116. https://doi.org/10.1016/j.jtha.2023.07.030

Vancouver

Kenet G, Young G, Chuansumrit A, Matsushita T, Yadav V, Zak M, et al. The immunogenicity, safety, and efficacy of N8-GP in previously untreated patients with severe hemophilia A: pathfinder6 end-of-trial results. Journal of Thrombosis and Haemostasis. 2023;21(11):3109-3116. doi:10.1016/j.jtha.2023.07.030

BibTeX
@article{Kenet2023,
  author = {Kenet, Gili and Young, Guy and Chuansumrit, Ampaiwan and Matsushita, Tadashi and Yadav, Vandana and Zak, Marek and Male, Christoph},
  title = {The immunogenicity, safety, and efficacy of N8-GP in previously untreated patients with severe hemophilia A: pathfinder6 end-of-trial results},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2023},
  volume = {21},
  number = {11},
  pages = {3109--3116},
  doi = {10.1016/j.jtha.2023.07.030}
}
Kostenlos starten →